atorvastatin / Generic mfg. - LARVOL DELTA

Cyclodextrin metal-organic framework engineered titanium surface: Targeted modulation of foam cell lipid homeostasis and inflammatory resolution. (PubMed, Colloids Surf B Biointerfaces) - "Our study fabricated a β/γ-CD-MOF composite via β-CD and γ-CD hybridization, incorporating the hydrophobic anti-inflammatory agent atorvastatin, followed by surface hydrophobic modification using stearic acid...By concurrently suppressing macrophage lipid uptake (cholesterol and oxidized low-density lipoprotein) and attenuating inflammatory cytokine expression, the coating synergistically retards atherosclerotic progression. Collectively, this stabilized coating presents a novel approach for achieving the long-term stability of CD-MOFs and facilitating the surface modification of vascular stents."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation

LDL-CHOLESTEROL LOWERING WITH ATORVASTATIN, ROSUVASTATIN AND SIMVASTATIN: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY. (PubMed, Georgian Med News) - "Rosuvastatin and atorvastatin were associated with greater LDL-cholesterol reduction compared with simvastatin in primary health care. Combination therapy with ezetimibe significantly increased the likelihood of achieving therapeutic LDL targets."

Journal • Observational data • Retrospective data • Cardiovascular • Dyslipidemia

Dingxin recipe Ⅲ ameliorates atherosclerosis through stard4-mediated regulation of hepatic lipid metabolism. (PubMed, Phytomedicine) - "DXRIII attenuates atherosclerosis by upregulating hepatic Stard4 expression to restore lipid homeostasis and reduce lipid accumulation."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • ANGPTL4 • APOB • APOE • SCARB1

Vascular Endothelial Dysfunction in Sleep Apnea (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Columbia University | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

STATIN USE, LDL-C LEVELS, AND COGNITIVE DECLINE IN ALZHEIMER'S DISEASE: A SWEDISH REGISTRY- BASED COHORT STUDY (ADPD 2026) - "Statin use (simvastatin, atorvastatin, or rosuvastatin) was modeled as a time-varying exposure based on prescription data. Statin use, particularly simvastatin, was associated with slower cognitive decline among AD patients, especially those with higher LDL-C levels. These findings suggest that both statin therapy and lipid status may jointly influence cognitive trajectories in AD."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Dyslipidemia

LIPOPHILIC STATINS AND RISK OF PARKINSON'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS (ADPD 2026) - "While lipophilic statins overall did not significantly affect PD risk; certain lipophilic statins like simvastatin, lovastatin and atorvastatin, showed a significant protective effect. Further research is needed to confirm the neuroprotective potential and clinical applications of statins."

Retrospective data • Review • CNS Disorders • Dyslipidemia • Movement Disorders • Parkinson's Disease

AN UNUSUAL CASE OF CEREBELLAR ISCHEMIC STROKE INITIALLY PRESENTING AS ISOLATED HEMIFACIAL SPASM WITHOUT OTHER NEUROLOGICAL SYMPTOMS AND SIGNS (ADPD 2026) - "Her symptoms were improved by atorvastatin, antiplatelet medication and symptomatic medications including baclofen and clonazepam. For now, we report for the first time a rare manifestation of cerebellar ischemic stroke initially presenting isolated hemifacial spasm without other neurological symptoms and signs. As like this case, if there are abrupt-onset isolated hemifacial spasm, it should be considered diagnosis of cerebellar ischemic stroke."

Clinical • Cardiovascular • Ischemic stroke

Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. (PubMed, Int J Mol Sci) - "Atorvastatin co-treatment partially reversed a subset of CFZ-induced transcriptional changes, particularly within cholesterol biosynthesis and lipid-regulatory pathways (e.g., ACAT2 and ACTA1) but did not restore the CFZ-mediated downregulation of sarcomeric genes. Together, these findings define a multifactorial signature of deleterious CFZ-induced transcriptional changes and suggest that atorvastatin may provide partial metabolic, but not structural, cardio protection."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • ACTA1 • FLNC • PSMC1 • PSMC6 • PSMD1 • PSMD12

Stress-Inducible Transcription Factor NUPR1 Is Involved in the Inhibitory Effects Exerted by Statins on Insulin Action in ER-Positive Breast Cancer Cells. (PubMed, Cells) - "In this study, we investigated the effects of simvastatin, atorvastatin and rosuvastatin in BC cells stimulated by insulin. Consistent with these findings, survival analyses of large cohorts of patients revealed that high levels of NUPR1 are associated with poor BC prognosis. Overall, our results provide novel mechanistic evidence supporting the repositioning of statins in BC, particularly in tumors characterized by elevated IR expression and activity."

Journal • Breast Cancer • Dyslipidemia • Estrogen Receptor Positive Breast Cancer • Genetic Disorders • Hormone Receptor Positive Breast Cancer • Metabolic Disorders • Obesity • Oncology • Solid Tumor • ER • IR

Protein covalent modification and hepatic cytotoxicity of atorvastatin resulting from its metabolic activation. (PubMed, Arch Toxicol) - "Atorvastatin calcium (ATV) is a statin drug that reduces low-density lipoprotein cholesterol and is widely used for the prevention and treatment of hyperlipidemia and cardiovascular and cerebrovascular diseases. Pre-treatment with CYP3A inhibitor ketoconazole (KTC) significantly reduced both ATV-derived protein adduction and hepatocyte susceptibility to ATV cytotoxicity. The findings facilitate the understanding of the mechanisms involved in ATV's idiosyncratic toxicity through systematic characterization of a CYP3A-mediated bioactivation process."

Journal • Cardiovascular • CNS Disorders • Dyslipidemia • Hepatology • Liver Failure • Vascular Neurology

Targeting HIF-2α in Colorectal Cancer Reveals a Cholesterol Biosynthesis-Dependent Ferroptotic Vulnerability. (PubMed, bioRxiv) - "Targeting this pathway with clinically approved statins (atorvastatin, pitavastatin, simvastatin) synergized with PT2385 to suppress CRC cell growth, reduce colony formation, and enhance cell death...These effects are fully reversed by the ferroptosis inhibitor liproxstatin-1...In vivo, co-administration of PT2385 and atorvastatin significantly reduced tumor growth and increased ferroptotic cell death in xenografts, confirming the mechanistic link. Collectively, these findings uncover a metabolic vulnerability of CRC to dual HIF-2α and cholesterol biosynthesis inhibition, supporting a clinically actionable strategy that leverages safe, FDA-approved statins to potentiate HIF-2α-targeted therapy."

Journal • Colorectal Cancer • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • EPAS1

The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease. (PubMed, BMC Cardiovasc Disord) - P4 | "Early combination of EZ with AS, rather than a stepwise approach, significantly reduced LDL-C levels and improved LDL-C reduction target achievement compared to AS monotherapy in very high-risk patients with dyslipidemia with no new safety issues."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

Dermatomyositis Mimicking Statin-Induced Myopathy in A 62-Year-Old Woman. (PubMed, Eur J Case Rep Intern Med) - "Statin-induced dermatomyositis is a rare immune-mediated complication that may mimic rhabdomyolysis early in its presentation.Lack of clinical or biochemical improvement after statin withdrawal and intravenous hydration should raise suspicion for inflammatory myopathy.Cutaneous findings, seronegative myositis profile, and skin biopsy features are key to distinguishing dermatomyositis from necrotizing autoimmune myopathy."

Journal • Dermatomyositis • Immunology • Musculoskeletal Pain • Myositis • Oncology • Pain

HIGH-DOSE SIMVASTATIN AS A POTENTIAL TRIGGER FOR ANGIOEDEMA: A CASE REPORT FOR BROADER DIAGNOSTIC CONSIDERATION (WRMC 2026) - "This case describes a 68-year-old male who presented to the emergency department with tongue and lip swelling and was diagnosed with angioedema, initially attributed to lisinopril use...Furthermore, the patient was found to have a medical history of angioedema secondary to atorvastatin use...It also underscores the importance of thorough medication reconciliation and avoiding premature diagnoses of the most common etiology. Timeline illustrating the patient's clinical course, highlighting angioedema episodes and treatment interventions over time."

Case report • Clinical • Cardiovascular

EFFECTIVENESS OF STATIN THERAPY FOR ELEVATED LIPID LEVELS IN PATIENTS ON MTOR INHIBITORS AFTER HEART TRANSPLANTATION (WRMC 2026) - "Randomized control trials have demonstrated that one therapeutic strategy to slow the progression of CAV is the use of mTOR inhibitors (mTORi), including sirolimus and everolimus...Methods Used: Between 2010 to 2024, we assessed 41 HTx recipients who were transitioned from pravastatin, a low potency statin, to a high potency statin, specifically rosuvastatin or atorvastatin, after initiating mTORi therapy... Switching patients to high potency statin therapy effectively lowered lipid levels in heart transplant recipients on mTORis. Statin intensification (select dosing) appears safe and well tolerated in this population."

Clinical • Cardiovascular • Dyslipidemia • Metabolic Disorders • Transplantation

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease (clinicaltrials.gov) - P=N/A | N=120 | Not yet recruiting | Sponsor: Taipei Veterans General Hospital, Taiwan

New trial • Ophthalmology • Thyroid Eye Disease

Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes. (PubMed, Hepatology) - "Mitochondrial and metabolic dysregulation are central to the pathogenesis of PLD. Targeting cholesterol metabolism with statins represents a promising therapeutic strategy to slow disease progression and reduce cyst burden."

Journal • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Transplantation

Relevance of Lesion Volume as an Outcome in Cerebral Cavernous Malformation Drug Trial (ISC 2026) - P1/2 | "Background: It is not clear if changes in lesion volume might represent a clinically relevant and statistically advantageous outcome parameter in early phase trials of novel drugs aimed at preventing bleeding in cerebral cavernous malformations (CCM). We analyzed the modified intention to treat cohort (33 patients receiving atorvastatin and 31 placebo) who contributed at least one paired imaging biomarker in the recently completed double-blinded randomized controlled AT CASH EPOC trial (clinicaltrials.gov NCT02603328)... Changes in lesion volume occur frequently in CCM lesions after recent SH, but do not correlate with measures of bleeding in the lesions, nor appear to reflect functional changes. And they are not statistically advantageous in comparison to QSM measures for detecting potential drug effects."

Hematological Disorders

Assessment of Functional Outcome in the AT CASH EPOC Trial of Hemorrhagic Cerebral Cavernous Malformations (ISC 2026) - "Atorvastatin did not influence functional change over 2 years by any measure. PROMIS Sleep Disturbance and EQ-VAS demonstrated high specificity, and in the case of EQ-VAS also a high sensitivity for identifying SH. Functional outcomes across domains also had high specificity for occult bleeding in CCMs as measured by QSM."

CNS Disorders • Hematological Disorders • Sleep Disorder

PCSK9 Inhibitor with Statin Therapy for Intracranial Artery Stenosis (PISTIAS): Design and Current Status of a Multicenter Randomized Controlled Trial (ISC 2026) - P4 | "Patients with acute ischemic stroke or transient ischemic attack (TIA) attributed to ICAS (50%-99%) and within 2 weeks of symptom onset will be recruited and randomized.Intervention: Eligible patients will be randomized 1:1 to receive biweekly subcutaneous Evolocumab (140mg) and statin therapy (rosuvastatin 20mg or atorvastatin 40mg) or statin therapy alone for 24 weeks.Outcome measures: The primary end point is the change in intracranial plaque burden assessed by high-resolution magnetic resonance imaging from baseline to week 24. Recruitment and follow-up are ongoing.Principal Investigator: Prof. Weihai Xu, Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Email: xuwh@pumch.cn.Sponsor: This work was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences and the Noncommunicable Chronic Diseases-National Science and Technology Major Project.Trial..."

Clinical • Atherosclerosis • Cardiovascular • Dyslipidemia • Ischemic stroke

Assessing the impact of PCSK9 inhibition on carotid or vertebral plaque phenotype with high resolution imaging (ISC 2026) - "A maximum of 200 patients will be randomized and treated for 26 weeks to compare the efficacy of evolocumab with atorvastatin or rosuvastatin in the treatment of carotid artery or vertebral plaques. During follow-up visits, at weeks 4, 12, and 26 after treatment, blood is sampled for fasting lipid profile testing. All patients are to be followed up regardless of whether they are taking study drug.Outcomes: The primary end point was the change in the minimum FCT from baseline to the 26-week follow-up assessed by OCT.Analysis: The main analysis method of the primary endpoint was to use the analysis of covariance (ANCOVA) model, including the treatment group and stratification factors, and the baseline FCT was the covariate."

Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure

Trans-ancestry Validation of a European-Derived Polygenic Risk Score for Statin Response in Young Korean Ischemic Stroke Patients: Results from the GENE_YAS Study (ISC 2026) - "Multivariable logistic regression models estimated the association between PRS and treatment goals (LDL-C <70 mg/dL or ≥50% reduction), adjusting for age, sex, and atorvastatin-equivalent dose. Mean age was 47.0 years, 72.4% were male, and baseline LDL-C was 119.3±40.5 mg/dL... Mean age was 47.0 years, 72.4% were male, and baseline LDL-C was 119.3±40.5 mg/dL. Follow-up LDL-C decreased progressively across PRS quartiles (Q1: 81.4 mg/dL; Q2: 79.3 mg/dL; Q3: 75.4 mg/dL; Q4: 70.2 mg/dL; p<0.001). Percentage reduction increased from 27.5% in Q1 to 32.8% in Q4 (p=0.018)."

Clinical • Cardiovascular • Dyslipidemia • Ischemic stroke

Recurrent Symptomatic Hemorrhage after Discontinuation of Atorvastatin versus Placebo in Randomized Trial of Hemorrhagic Cerebral Cavernous Malformations (ISC 2026) - P1/2 | "This raises concern for a rebound effect during the year after statin withdrawal in hemorrhagic CCM patients, potentially mediated by reactivation of Rho-associated kinase. Additional studies are warranted to confirm these observations and to assess whether statin tapering or maintenance therapy can mitigate the risk of discontinuation in hemorrhagic CCM."

Clinical • Cerebral Hemorrhage • Hematological Disorders

Comparative Efficacy of Interventions for Supratentorial Stroke: A Bayesian NMA with Meta-Regression (ISC 2026) - "Pharmacologic options (e.g., tranexamic acid, atorvastatin, cerebrolysin) showed no significant benefit for mortality or function compared with standard care. For acute supratentorial ICH, surgical approaches—especially minimally invasive endoscopic evacuation—yield superior 6-month survival and functional outcomes compared with medical therapy alone. Conventional craniotomy confers a moderate survival advantage. Pharmacologic adjuncts did not improve hard outcomes in this network."

Clinical • Cardiovascular

Experimental and Finite Element Analysis of a Residual Hair Keratin-based Hydrogel with Calcium for Atorvastatin Sequestration, Release, and In Vitro Activity. (PubMed, Macromol Biosci) - "In vitro assays confirmed CKRT biocompatibility (ISO 10993-5) and preserved Ator bioactivity, with EC50 values of 208 µm for mesenchymal stem and 389 µm for fibroblast cell lines. These findings demonstrate that CKRT provides a robust platform for controlled anti-fibrotic drug delivery, supported by extensive physicochemical and mechanical characterization."

Journal • Preclinical • Fibrosis • Immunology